Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.76, 2013, Pages

  Montanelli, Gaia ^a   Beretta, Lorenzo ^a   Santaniello, Alessandro ^a   Scorza, Raffaella ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Calcium channel blockers; Coxregression; Prednisone; Scleroderma renal crisis; Systemic sclerosis

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; ILOPROST; PREDNISONE; CALCIUM CHANNEL L TYPE; GLUCOCORTICOID; PREDNISOLONE; VASODILATOR AGENT;

ADULT; ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HYPERTENSION; ITALY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SCLERODERMA RENAL CRISIS; SYSTEMIC SCLEROSIS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTOR;

ADULT; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; FEMALE; GLUCOCORTICOIDS; HUMANS; ILOPROST; ITALY; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISOLONE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, SYSTEMIC; VASODILATOR AGENTS;

EID: 84883806186     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. PENN H, HOWIE AJ, KINGDON EJ et al.: Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100: 485-94.
2. CODULLO V, CAVAZZANA I, BONINO C et al.: Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 2009; 36: 1464-9.
3. SIMEON CP, ARMADANS L, FONOLLOSA V et al.: Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997; 56: 723-8.
4. VLACHOYIANNOPOULOS PG, DAFNI UG, PAKAS I, SPYROPOULOU-VLACHOU M, STAVROPOULOS-GIOKAS C, MOUTSOPOULOS HM: Systemic scleroderma in Greece: Low mortality and strong linkage with HLADRB1*1104 allele. Ann Rheum Dis 2000; 59: 359-67.
5. MAYES MD, LACEY JV Jr., BEEBE-DIMMER J et al.: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246-55.
6. TEIXEIRA L, MOUTHON L, MAHR A et al.: Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67: 110-6.
7. STEEN VD, MEDSGER TA: Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
8. STEEN VD, COSTANTINO JP, SHAPIRO AP, MEDSGER TA Jr.: Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352-7.
9. STEEN VD, MEDSGER TA Jr.: Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 600-3.
10. STEEN VD: Scleroderma renal crisis. Rheum Dis Clin North Am 2003; 29: 315-33.
11. BATAL I, DOMSIC RT, MEDSGER TA, BASTACKY S: Scleroderma renal crisis: a pathology perspective. Int J Rheumatol 2010; 2010: 543704.
12. CANNON PJ, HASSAR M, CASE DB, CASARELLA WJ, SOMMERS SC, LEROY EC: The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore) 1974; 53: 1-46.
13. STEEN VD, MEDSGER TA Jr, OSIAL TA Jr, ZIEGLER GL, SHAPIRO AP, RODNAN GP: Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76: 779-86.
14. DeMARCO PJ, WEISMAN MH, SEIBOLD JR et al.: Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983-9.
15. KOWAL-BIELECKA O, LANDEWÉ R, AVOUAC J et al.: EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-8.
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma): Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutics Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
17. LeROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 1988; 15: 202-5.
18. BAYER PM, BAUERFEIND S, BIENVENU J et al.: Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay. J Autoimmun 1999; 13, 89-93.
19. MUKERJEE D, St GEORGE D, KNIGHT C et al.: Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 461-6.
20. SCUSSEL-LONZETTI L, JOYAL F, RAYNAULD JP et al.: Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 154-67.
21. KORN JH, MAYES M, MATUCCI-CERINIC M et al.: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985-93.
22. SCORZA R, CARONNI M, MASCAGNI B et al.: Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001; 19: 503-8.
23. FISHER LD, LIN DY: Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999; 20: 145-57.
24. HAYASHI K, NAGAHAMA T, OKA K, EPSTEIN M, SARUTA T: Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 1996; 19: 31-6.
25. LOUTZENHISER R, EPSTEIN M: Renal microvascular actions of calcium antagonists. J Am Soc Nephrol 1990; 1: S3-12.
26. LOUTZENHISER RD, EPSTEIN M, FISCHETTI F, HORTON C: Effects of amlodipine on renal hemodynamics. Am J Cardiol 1989; 64: 122I-127I.
27. RODICIO JL: Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000; 35:S7-11.
28. ANDREONI KA, O'DONNELL CP, BURDICK JF, ROBOTHAM JL: Hepatic and renal blood flow responses to a clinical dose of intravenous cyclosporine in the pig. Immunopharmacology 1994; 28: 87-94.
29. MEYER O, De CHAISEMARTIN L, NICAISEROLAND P et al.: Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a crosssectional study. J Rheumatol 2010; 37: 125-30.
30. VITTINGHOFF E, McCULLOCH CE: Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165: 710-8.
31. van WALRAVEN C, DAVIS D, FORSTER AJ, WELLS GA: Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 2004; 57: 672-82.
32. SY RW, BANNON PG, BAYFIELD MS, BROWN C, KRITHARIDES L: Survivor treatment selection bias and outcomes research: a case study of surgery in infective endocarditis. Circ Cardiovasc Qual Outcomes 2009; 2: 469-74.
33. STEEN V, MEDSGER TA Jr.: Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22.
34. VIGNAUX O, ALLANORE Y, MEUNE C et al.: Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 2005; 64: 1268-73.
35. ALLANORE Y, MEUNE C, VONK MC et al.: Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010; 69: 218-21.